
Indications and Usage
Indications and Usage
APTIVUS, a protease inhibitor co-administered with ritonavir (APTIVUS/r), is indicated for combination antiretroviral treatment of HIV infected patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.
This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/r of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients age 2 to 18 years. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
The following points should be considered when initiating therapy with APTIVUS/r:
- The use of APTIVUS/r in treatment-naïve patients is not recommended.
- The use of other active agents with APTIVUS/r is associated with a greater likelihood of treatment response.
- Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/r. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/r.
- Use caution when prescribing APTIVUS/r to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment.
- Liver function tests should be performed at initiation of therapy with APTIVUS/r and monitored frequently throughout the duration of treatment.
- The drug-drug interaction potential of APTIVUS/r when co-administered with other drugs must be considered prior to and during APTIVUS/r use.
- Use caution when prescribing APTIVUS/r in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding.
- The risk-benefit of APTIVUS/r has not been established in pediatric patients less than 2 years of age.
There are no study results demonstrating the effect of APTIVUS/r on clinical progression of HIV-1.
APTIVUS/r does not cure HIV or help prevent passing HIV to others.Please consult the Full Prescribing Information ,including boxed WARNINGS, and Important Safety Information for APTIVUS, as well as information on the RESIST Trials.

